​

Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GILD Stock Forecast

Gilead Sciences (GILD) stock forecast, based on 58 Wall Street analysts, predicts a 12-month average price target of $158.71, with a high of $180.00 and a low of $105.00. This represents a 15.95% increase from the last price of $136.88.

$50 $80 $110 $140 $170 $200 High: $180 Avg: $158.71 Low: $105 Last Closed Price: $136.88

GILD Stock Rating

Gilead Sciences stock's rating consensus is Buy, based on 58 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 37 Buy (63.79%), 20 Hold (34.48%), 1 Sell (1.72%), and 0 Strong Sell (0.00%).

Buy
Total 58 1 20 37 Strong Sell Sell Hold Buy Strong Buy

GILD Price Target Upside V Benchmarks

TypeNameUpside
StockGilead Sciences15.95%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks7.80%

Price Target Trends

1M3M12M
# Anlaysts12138
Avg Price Target$180.00$159.14$147.97
Last Closing Price$136.88$136.88$136.88
Upside/Downside31.50%16.26%8.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 265177-130
Feb, 265176-129
Jan, 265168--29
Dec, 255168--29
Nov, 254168--28
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 10, 2026Akash TewariJefferies$180.00$146.9422.50%31.50%
Feb 19, 2026Barclays$155.00$151.122.57%13.24%
Feb 19, 2026Mizuho Securities$170.00$152.7411.30%24.20%
Feb 18, 2026UBS$175.00$155.2712.71%27.85%
Feb 11, 2026Louise ChenScotiabank$177.00$155.2913.98%29.31%
Feb 11, 2026Morgan Stanley$171.00$155.729.81%24.93%
Feb 11, 2026Truist Financial$162.00$155.873.93%18.35%
Feb 11, 2026Truist Financial$152.00$154.69-1.74%11.05%
Feb 11, 2026Oppenheimer$165.00$153.467.52%20.54%
Feb 11, 2026Cantor Fitzgerald$155.00$147.235.28%13.24%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2026JefferiesBuyBuyinitialise
Mar 06, 2026Bank of America SecuritiesBuyBuyhold
Feb 18, 2026UBSBuyBuyhold
Feb 11, 2026ScotiabankOutperformOutperformhold
Feb 11, 2026BernsteinOutperformOutperformhold
Feb 11, 2026Morgan StanleyOverweightOverweighthold
Feb 11, 2026Bank of America SecuritiesBuyBuyhold
Feb 11, 2026OppenheimerOutperformOutperformhold
Feb 11, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 11, 2026NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$0 $2 $4 $6 $8 $10 $11 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.96$3.66$4.54$0.38$6.84---
Avg Forecast$8.20$7.10$6.75$4.38$7.59$7.95$8.47$9.07
High Forecast$8.53$7.42$7.05$4.72$8.42$9.84$10.05$9.61
Low Forecast$7.96$6.84$6.58$3.87$6.40$5.77$5.94$8.66
Surprise %-39.51%-48.45%-32.74%-91.32%-9.88%---

Revenue Forecast

$26B $27B $29B $31B $32B $34B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$27.30B$27.28B$27.12B$28.75B$29.44B---
Avg Forecast$26.67B$26.53B$27.10B$28.32B$28.49B$29.34B$30.74B$32.22B
High Forecast$27.48B$27.44B$27.28B$28.60B$29.85B$29.36B$30.85B$33.68B
Low Forecast$26.05B$25.78B$26.91B$28.10B$27.87B$29.31B$30.63B$31.10B
Surprise %2.38%2.84%0.06%1.54%3.34%---

Net Income Forecast

$0 $3B $6B $9B $12B $15B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.22B$4.59B$5.67B$480.00M$8.51B---
Avg Forecast$5.09B$3.23B$5.67B$5.40B$9.33B$7.55B$8.20B$11.41B
High Forecast$6.10B$3.88B$6.80B$5.94B$10.60B$12.37B$12.64B$12.09B
Low Forecast$4.07B$2.58B$4.53B$4.87B$8.06B$7.26B$7.47B$10.90B
Surprise %22.36%42.16%--91.12%-8.75%---

GILD Forecast FAQ

Is Gilead Sciences stock a buy?

Gilead Sciences stock has a consensus rating of Buy, based on 58 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 37 Buy, 20 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Gilead Sciences is a favorable investment for most analysts.

What is Gilead Sciences's price target?

Gilead Sciences's price target, set by 58 Wall Street analysts, averages $158.71 over the next 12 months. The price target range spans from $105 at the low end to $180 at the high end, suggesting a potential 15.95% change from the previous closing price of $136.88.

How does Gilead Sciences stock forecast compare to its benchmarks?

Gilead Sciences's stock forecast shows a 15.95% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (7.80%).

What is the breakdown of analyst ratings for Gilead Sciences over the past three months?

  • March 2026: 16.67% Strong Buy, 56.67% Buy, 23.33% Hold, 0% Sell, 3.33% Strong Sell.
  • February 2026: 17.24% Strong Buy, 58.62% Buy, 20.69% Hold, 0% Sell, 3.45% Strong Sell.
  • January 2026: 17.24% Strong Buy, 55.17% Buy, 27.59% Hold, 0% Sell, 0% Strong Sell.

What is Gilead Sciences’s EPS forecast?

Gilead Sciences's average annual EPS forecast for its fiscal year ending in December 2026 is $7.95, marking a 16.23% increase from the reported $6.84 in 2025. Estimates for the following years are $8.47 in 2027, and $9.07 in 2028.

What is Gilead Sciences’s revenue forecast?

Gilead Sciences's average annual revenue forecast for its fiscal year ending in December 2026 is $29.34B, reflecting a -0.37% decrease from the reported $29.44B in 2025. The forecast for 2027 is $30.74B, and $32.22B for 2028.

What is Gilead Sciences’s net income forecast?

Gilead Sciences's net income forecast for the fiscal year ending in December 2026 stands at $7.55B, representing a -11.31% decrease from the reported $8.51B in 2025. Projections indicate $8.2B in 2027, and $11.41B in 2028.